The University of Tokyo and BrightPath Biotherapeutics Jointly Register Patent for Rejuvenated Antigen-specific T Lymphocytes Using iPS Cells
On July 24, 2017, the University of Tokyo and BrightPath Biotherapeutics Co., Ltd. jointly announced the issuance of a patent for generating rejuvenated antigen-specific T lymphocytes using iPS cells. This breakthrough was achieved in the laboratory of Professor Hiromitsu Nakauchi, at the Institute of Medical Science, the University of Tokyo. This patent has been exclusively licensed to Advanced Immunotherapy Co., Ltd. (a subsidiary of BrightPath Biotherapeutics) and is being co-developed for future use. For details, please see the Institute of Medical Science's website and the full press release linked below.
General public / Enrolled students / Applying students / International students / Alumni / Companies